Treatment of chronic hepatitis delta with pegylated interferon‐α2b

Erhardt, Andreas; Gerlich, Wolfram H.; Starke, Christine; Wend, Ulrike C.; Donner, Andreas; Sagir, Abdurrahman; Heintges, Tobias; Häussinger, Dieter

doi:10.1111/j.1478-3231.2006.01279.x

Cited by 134 publications

(122 citation statements)

References 32 publications

Supporting

Mentioning

109

Contrasting

Unclassified

Order By: Relevance

“…In this study, as in previous studies, 4,6 the pattern of HDV RNA expression during therapy was somewhat inconsistent. Relapses occurred in patients who had cleared HDV RNA while on therapy and viral clearance was observed during the follow-up in patients who had detectable levels of HDV RNA at the end of therapy.…”

supporting

confidence: 61%

PEG-IFN for the treatment of hepatitis D

Ciancio

Rizzetto

2011

Nat Rev Gastroenterol Hepatol

View full text Add to dashboard Cite

show abstract

supporting

confidence: 61%

PEG-IFN for the treatment of hepatitis D

Ciancio

Rizzetto

2011

Nat Rev Gastroenterol Hepatol

View full text Add to dashboard Cite

show abstract

“…Niro et al found virological and biochemical response rates at the EOT to be 19% and 37% and sustained virological and biochemical response rates to be 21% and 26%, respectively (14). However, in 2 other series of patients treated with the same PEG-interferon, an SVR was obtained only in 17% and 21% of the patients (15,16). The results of the current study appear to show slightly higher virological, biochemical, and histological response rates, at 27 (58.6%), 16 (34.7%), and 39 (84.7%) at the EOT, and sustained virological and biochemical response rates of 41% and 47.8%, respectively.…”

Section: Discussionmentioning

confidence: 99%

Treatment of Chronic Delta Hepatitis: A Nine-Year Retrospective Analysis

2011

View full text Add to dashboard Cite

A B S T R A C TBackground: Chronic delta hepatitis is the most severe form of viral hepatitis, for which interferon administration is the only available treatment. However, the efficacy of interferon treatment is affected by the dose and duration of treatment, and relapse rates are high. Objectives: In this study, we sought to evaluate the efficacy of treatment with pegylated interferon and observe the relapse rates of delta hepatitis after treatment. Patients and Methods: Forty-six patients with chronic delta hepatitis were retrospectively studied between January 2002 and December 2010. Patients were evaluated for biochemical, virological, and histological responses. They were then followed-up for at least 1 year after discontinuation of the treatment. Results: All the 46 patients in the study received PEG-IFN therapy. Of the 46 patients, 25 were treated with PEG-IFN for 1 year and 21 were treated for 2 years. Sixteen patients (34.7%) showed a biochemical response, 27 (58.6%) showed a virological response, and 39 (84.7%) showed a histological response. Sustained virological and biochemical responses were achieved in 41% and 47.8% of the patients, respectively. Sixteen (84.2%) patients of the 19 with high levels of hepatitis delta virus RNA (HDV RNA) (HDV RNA level > 1 × 105) and 10 (71.4%) of the 14 patients with high titers of hepatitis B surface antigen (HbsAg) (HbsAg > 102 IU/mL) at the beginning of the treatment showed relapse after treatment. Conclusions: We found no significant differences between 1-year and 2-year treatments. However, the relapse rate was lower in the 2-year treatment group. Higher HDV RNA and HbsAg levels before treatment were associated with higher relapse rates. Younger age was a significant factor in predicting response.

show abstract

“…The most important thing is that in those who responded, histological improvement was maintained even after 10 years [55]. In another trial, PEG-IFN-a-2b was administered in 12 patients and HDV-RNA was undetectable at 6 months in 17%, while responders also demonstrated histological improvement compared with nonresponders [56]. Among patients who did not have a 3log10 decline of HDV-RNA 6 months after initiation of treatment, none achieved a lasting response (negative-predictive value: 100%).…”

Section: Hdv Coinfectionmentioning

confidence: 99%